Research Site
Springfield, Missouri, United States
NCT Number: NCT01154621
The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 1
Springfield, Missouri, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
Sterile 5% dextrose solution
Time frame: The screening period is up to 28 days. Residential period will be a total of 5 days. Follow up will occur between 5 and 10 days after discharge.
Adverse events, vital signs, electrocardiograms, telemetry, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment
Time frame: Blood and urine samples will be collected for the 4 days while in residence.
AstraZeneca
Industry
A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06633562
Healthy, Safety Evaluation of Escalating Doses
La Jolla, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT07660107
Safety, Tolerability
Boulder, Colorado, United States
View Trial DetailsNCT06770491
Brain Diseases, Cardiovascular Diseases
Webster, Texas, United States
View Trial Details